Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of citrate/heparin/taurolidine (Neutrolin) for the prevention of catheter-related infections in cancer patients receiving total parenteral nutrition

Trial Profile

Phase III trial of citrate/heparin/taurolidine (Neutrolin) for the prevention of catheter-related infections in cancer patients receiving total parenteral nutrition

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Citrate/heparin/taurolidine (Primary)
  • Indications Bacterial infections; Catheter infections; Catheter thrombosis; Mycoses
  • Focus Registrational; Therapeutic Use
  • Acronyms LOCK-IT 200
  • Sponsors CorMedix
  • Most Recent Events

    • 15 Sep 2016 According to CorMedix media release, company may submit this and the other study (700250714) to the FDA for potential approval for both patient populations.
    • 05 Aug 2016 According to a CorMedix media release, company anticipates a meeting with the FDA to finalize the protocol in 4Q 2016.
    • 11 May 2016 According to a CorMedix media release, the company is planning to initiate pharmacoeconomic studies within LOCK-IT 100 and LOCK-IT 200 studies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top